

CNMV  
Edison, 4  
28006 Madrid

Barcelona, July 22, 2016

RELEVANT FACT

Dear Sir,

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated October 23, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), submits hereafter press release on the job creation occurred in order to strengthens its workforce to face new ongoing projects.

Yours faithfully,

Adolf Rousaud  
Secretary of the Board of Directors  
Laboratorio Reig Jofre SA

## Important job creation in Spain

### REIG JOFRE STRENGTHENS ITS WORKFORCE AND EXCEEDS 910 EMPLOYEES TO FACE NEW ONGOING PROJECTS

- Reig Jofre reached 911 employees at the end of June 2016, after increasing its workforce by 72 people in the last twelve months.
- New recruitments were mainly in Spain, in the areas of production, R&D and sales teams.
- The company is implementing a determined investment policy to address ongoing industrial and commercial projects, which includes expansion of workforce and productive capacity and new investments in R&D.

**Barcelona, July 22, 2016.** The pharmaceutical company Reig Jofre closed June 2016 with a considerable job creation, which exceeded 72 new recruitments in the last twelve months. Reig Jofre's team grew about 6% in the period and reached 911 employees, 55% women and 45% men.

In these past months, almost all of the recruitments were concentrated in Spain and in particular in the areas of production capacity, R&D and sales force.

If 2015 was the year of integration following the merger between the former Reig Jofre and Natraceutical, in 2016 the company is increasing its investments to strengthen its operational structure in order to meet ongoing growth projects.

In this sense, in 2016 Reig Jofre plans to invest around 8.5 million euros to increase its production capacity in Toledo and Barcelona, complete the construction of a new development-, analysis- and quality control laboratory; and boost its R&D. In addition, around 3 million euros more than in the first half of 2015 were addressed in the first six months of the year, via profit and loss account, to strengthen the workforce, R&D projects and the marketing strategy to support its brands.



In Spain, the company has two independent plants in Toledo specialized and dedicated exclusively to the development and manufacturing of beta-lactam antibiotics (penicillanic and cephalosporins); a plant in Barcelona, specialized in the development and manufacture of sterile injectables for hospital use, which also manufactures all other kinds of solid, semi-solid and liquid oral forms; as well as an R&D center in each plant and its own sales team with over 100 sales reps.

Outside Spain, Reig Jofre has a development and manufacture plant in Sweden, specialized in topical dermatological products; and own sales network in France, Benelux, Portugal, United Kingdom, Sweden and Singapore. Also, the company has commercial presence in 58 countries worldwide through more than 130 partners and licensees.

Currently, markets outside Spain account for 60% of Reig Jofre's sales, where it is expected to continue growing, as shown by the recent entry into Japan with the commercialization of an injectable for hospital use and in Hong Kong and Macao with Forté Pharma's products, the line of Reig Jofre's nutritional supplements.

Reig Jofre closed 2015 with a financial leverage below one time EBITDA and has repeatedly expressed its willingness to continue investing in growth opportunities, a fact that the company might combine with the setting up of a dividend policy on 2016 results.

The company plans to release 2016 first half year results on Tuesday July 26, before the stock market opening.

Receive Reig Jofre's news by registering in the company's **subscription center** of the new corporate website: **[www.reigjofre.com](http://www.reigjofre.com)**

### **About Reig Jofre**

After the merger between Laboratorio Reig Jofre and Natraceutical, the new Reig Jofre is a pharmaceutical company whose business is divided into two major areas: one main for the marketing and manufacture of own developments (RJF Pharma, approximately 79% of sales in 2015) and one of specialized contract development and manufacturing (RJF CDMO, 21% of sales in 2015). At its core activity, the company focuses on the development of technological-specialization products (beta-lactam antibiotics, injectable and freeze-dried products); therapeutic-specialization products in the areas of dermatology, respiratory/ENT and gynaecology; and food supplements and consumer healthcare. The company directs its R&D to develop new indications and/or dosage forms of already-known active ingredients, generic medicines with a special focus on the development of injectable, freeze-dried and generic beta-lactam antibiotics, topical dermatological products, OTCs and food supplements as well as the development of new innovative molecules in partnership with start-ups and biotech research centres.



Reig Jofre trades on the Spanish stock exchange under the ticker RJF. Share capital: 63,214,220.

### **For further information**

---

#### **Investors and analysts**

Gloria Folch  
Tel. (+34) 93 480 67 10 – ext. 1241  
gloria.folch@reigjofre.com

#### **Media**

Inma Santa-Pau  
Tel. (+34) 93 480 67 10 – ext. 1242  
inma.santapau@reigjofre.com